Feb 11 (Reuters) - U.S. health regulators approved Thermo Fisher Scientific Inc’s test that can help prevent organ damage in kidney transplant patients by monitoring level of the immunosuppressant everolimus.
Some immunosuppressants are associated with toxic side effects that can injure transplanted kidneys.
Thermo Fisher’s test QMS Everolimus Immunoassay monitors the blood level of Novartis’s everolimus, which suppresses the immune system to prevent organ rejection.
Shares of Thermo Fisher closed up 1.5 percent at $57.85 on Friday on the New York Stock Exchange. (Reporting by Anand Basu in Bangalore; Editing by Joyjeet Das)